TEST BANK FOR
PHARMACOLOGY A PATIENT-CENTERED NURSING PROCESS APPROACH, 11TH
EDITION
BY LINDA E. MCCUISTION | VERIFIED CHAPTER'S 1 - 58 | COMPLETE ANSWERS
,TABLE OF CONTENTS
CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE ........................................................ 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS ...................................................... 11
CHAPTER 03: PHARMACOKINETICS AND PHARMACODYNAMICS .............................................................. 22
CHAPTER 04: PHARMACOGENETICS ........................................................................................................... 40
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................................... 45
CHAPTER 06: PEDIATRIC CONSIDERATIONS................................................................................................ 51
CHAPTER 07: GERIATRIC CONSIDERATIONS ............................................................................................... 60
CHAPTER 08: DRUGS IN SUBSTANCE USE DISORDER.................................................................................. 67
CHAPTER 09: SAFETY AND QUALITY ........................................................................................................... 75
CHAPTER 10: DRUG ADMINISTRATION ....................................................................................................... 83
CHAPTER 11: DRUG CALCULATIONS ........................................................................................................... 89
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ..................................................................................... 95
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ............................................................................. 107
CHAPTER 14: NUTRITIONAL SUPPORT ...................................................................................................... 116
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ..................................................................... 126
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................................... 133
CHAPTER 17: STIMULANTS ....................................................................................................................... 142
CHAPTER 18: DEPRESSANTS...................................................................................................................... 147
CHAPTER 19: ANTISEIZURE DRUGS ........................................................................................................... 156
CHAPTER 20: DRUGS FOR PARKINSONISM AND ALZHEIMER DISEASE ..................................................... 165
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS .................................. 173
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS .................................................................................. 181
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ..................................................................... 190
CHAPTER 24: ANTIINFLAMMATORIES....................................................................................................... 199
CHAPTER 25: ANALGESICS ........................................................................................................................ 208
CHAPTER 26: PENICILLINS, OTHER BETA-LACTAMS, AND CEPHALOSPORINS .......................................... 217
CHAPTER 27: MACROLIDES, OXAZOLIDINONES, LINCOSAMIDES, GLYCOPEPTIDES, KETOLIDES, AND
LIPOPEPTIDES ............................................................................................................................................ 224
CHAPTER 28: TETRACYCLINES, GLYCYLCYCLINES, AMINOGLYCOSIDES, AND FLUOROQUINOLONES ...... 229
CHAPTER 29: SULFONAMIDES AND NITROIMIDAZOLES ANTIBIOTICS ..................................................... 234
CHAPTER 30: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ....................................................... 240
CHAPTER 31: ANTIMALARIALS, ANTHELMINTICS, AND PEPTIDES ............................................................ 251
,CHAPTER 32: HIV- AND AIDS-RELATED DRUGS ......................................................................................... 255
CHAPTER 33: TRANSPLANT DRUGS ........................................................................................................... 260
CHAPTER 34: VACCINES ............................................................................................................................ 263
CHAPTER 35: ANTICANCER DRUGS ........................................................................................................... 269
CHAPTER 36: TARGETED THERAPIES TO TREAT CANCER .......................................................................... 275
CHAPTER 37: BIOLOGIC RESPONSE MODIFIERS ........................................................................................ 280
CHAPTER 38: UPPER RESPIRATORY DISORDERS ....................................................................................... 287
CHAPTER 39: LOWER RESPIRATORY DISORDERS ...................................................................................... 293
CHAPTER 40: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................................... 302
CHAPTER 41: DIURETICS ........................................................................................................................... 314
CHAPTER 42: ANTIHYPERTENSIVES ........................................................................................................... 321
CHAPTER 43: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ............................................. 330
CHAPTER 44: ANTIHYPERLIPIDEMICS AND DRUGS TO IMPROVE PERIPHERAL BLOOD FLOW ................. 341
CHAPTER 45: GASTROINTESTINAL TRACT DISORDERS.............................................................................. 349
CHAPTER 46: ANTIULCER DRUGS .............................................................................................................. 359
CHAPTER 47: EYE AND EAR DISORDERS .................................................................................................... 368
CHAPTER 48: DERMATOLOGIC DISORDERS .............................................................................................. 374
CHAPTER 49: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ..................................... 381
CHAPTER 50: ANTIDIABETICS .................................................................................................................... 393
CHAPTER 51: URINARY DISORDERS .......................................................................................................... 404
CHAPTER 52: PREGNANCY AND PRETERM LABOR .................................................................................... 411
CHAPTER 53: LABOR, DELIVERY, AND POSTPARTUM ............................................................................... 422
CHAPTER 54: NEONATAL AND NEWBORN ................................................................................................ 429
CHAPTER 55: WOMEN’S REPRODUCTIVE HEALTH .................................................................................... 432
CHAPTER 56: MEN’S HEALTH AND REPRODUCTIVE DISORDERS .............................................................. 442
CHAPTER 57: SEXUALLY TRANSMITTED INFECTIONS ................................................................................ 448
CHAPTER 58: ADULT AND PEDIATRIC EMERGENCY DRUGS...................................................................... 453
, CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS
APPROACH, 11TH EDITION
MULTIPLE CHOICE
1. ALL OF THE FOLLOWING WOULD BE CONSIDERED SUBJECTIVE DATA, EXCEPT:
A. PATIENT-REPORTED HEALTH HISTORY
B. PATIENT-REPORTED SIGNS AND SYMPTOMS OF THEIR ILLNESS
C. FINANCIAL BARRIERS REPORTED BY THE PATIENT’S CAREGIVER
D. VITAL SIGNS OBTAINED FROM THE MEDICAL RECORD
ANSWER:D
SUBJECTIVE DATA IS BASED ON WHAT PATIENTS OR FAMILY MEMBERS COMMUNICATE TO THE
NURSE. PATIENT- REPORTED HEALTH HISTORY, SIGNS AND SYMPTOMS, AND CAREGIVER REPORTED
FINANCIAL BARRIERS WOULD BE CONSIDERED SUBJECTIVE DATA. VITAL SIGNS OBTAINED FROM THE
MEDICAL RECORD WOULD BE CONSIDERED OBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: PLANNING
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
2. THE NURSE IS USING DATA COLLECTED TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE MOST
DESIRABLE OUTCOMES. WHICH OF THE FOLLOWING STEPS IS THE NURSE APPLYING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. GENERATE SOLUTIONS (PLANNING)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANSWER:C
WHEN GENERATING SOLUTIONS (PLANNING), THE NURSE IDENTIFIES EXPECTED OUTCOMES AND USES
THE PATIENT’S PROBLEM(S) TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE MOST DESIRABLE
OUTCOMES. RECOGNIZING CUES (ASSESSMENT) INVOLVES THE GATHERING OF CUES (INFORMATION)
FROM THE PATIENT ABOUT THEIR HEALTH AND LIFESTYLE PRACTICES, WHICH ARE IMPORTANT FACTS
THAT AID THE NURSE IN MAKING CLINICAL CARE DECISIONS. PRIORITIZING HYPOTHESIS IS USED TO
PHARMACOLOGY A PATIENT-CENTERED NURSING PROCESS APPROACH, 11TH
EDITION
BY LINDA E. MCCUISTION | VERIFIED CHAPTER'S 1 - 58 | COMPLETE ANSWERS
,TABLE OF CONTENTS
CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE ........................................................ 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS ...................................................... 11
CHAPTER 03: PHARMACOKINETICS AND PHARMACODYNAMICS .............................................................. 22
CHAPTER 04: PHARMACOGENETICS ........................................................................................................... 40
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................................... 45
CHAPTER 06: PEDIATRIC CONSIDERATIONS................................................................................................ 51
CHAPTER 07: GERIATRIC CONSIDERATIONS ............................................................................................... 60
CHAPTER 08: DRUGS IN SUBSTANCE USE DISORDER.................................................................................. 67
CHAPTER 09: SAFETY AND QUALITY ........................................................................................................... 75
CHAPTER 10: DRUG ADMINISTRATION ....................................................................................................... 83
CHAPTER 11: DRUG CALCULATIONS ........................................................................................................... 89
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ..................................................................................... 95
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ............................................................................. 107
CHAPTER 14: NUTRITIONAL SUPPORT ...................................................................................................... 116
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ..................................................................... 126
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................................... 133
CHAPTER 17: STIMULANTS ....................................................................................................................... 142
CHAPTER 18: DEPRESSANTS...................................................................................................................... 147
CHAPTER 19: ANTISEIZURE DRUGS ........................................................................................................... 156
CHAPTER 20: DRUGS FOR PARKINSONISM AND ALZHEIMER DISEASE ..................................................... 165
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS .................................. 173
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS .................................................................................. 181
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ..................................................................... 190
CHAPTER 24: ANTIINFLAMMATORIES....................................................................................................... 199
CHAPTER 25: ANALGESICS ........................................................................................................................ 208
CHAPTER 26: PENICILLINS, OTHER BETA-LACTAMS, AND CEPHALOSPORINS .......................................... 217
CHAPTER 27: MACROLIDES, OXAZOLIDINONES, LINCOSAMIDES, GLYCOPEPTIDES, KETOLIDES, AND
LIPOPEPTIDES ............................................................................................................................................ 224
CHAPTER 28: TETRACYCLINES, GLYCYLCYCLINES, AMINOGLYCOSIDES, AND FLUOROQUINOLONES ...... 229
CHAPTER 29: SULFONAMIDES AND NITROIMIDAZOLES ANTIBIOTICS ..................................................... 234
CHAPTER 30: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ....................................................... 240
CHAPTER 31: ANTIMALARIALS, ANTHELMINTICS, AND PEPTIDES ............................................................ 251
,CHAPTER 32: HIV- AND AIDS-RELATED DRUGS ......................................................................................... 255
CHAPTER 33: TRANSPLANT DRUGS ........................................................................................................... 260
CHAPTER 34: VACCINES ............................................................................................................................ 263
CHAPTER 35: ANTICANCER DRUGS ........................................................................................................... 269
CHAPTER 36: TARGETED THERAPIES TO TREAT CANCER .......................................................................... 275
CHAPTER 37: BIOLOGIC RESPONSE MODIFIERS ........................................................................................ 280
CHAPTER 38: UPPER RESPIRATORY DISORDERS ....................................................................................... 287
CHAPTER 39: LOWER RESPIRATORY DISORDERS ...................................................................................... 293
CHAPTER 40: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................................... 302
CHAPTER 41: DIURETICS ........................................................................................................................... 314
CHAPTER 42: ANTIHYPERTENSIVES ........................................................................................................... 321
CHAPTER 43: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ............................................. 330
CHAPTER 44: ANTIHYPERLIPIDEMICS AND DRUGS TO IMPROVE PERIPHERAL BLOOD FLOW ................. 341
CHAPTER 45: GASTROINTESTINAL TRACT DISORDERS.............................................................................. 349
CHAPTER 46: ANTIULCER DRUGS .............................................................................................................. 359
CHAPTER 47: EYE AND EAR DISORDERS .................................................................................................... 368
CHAPTER 48: DERMATOLOGIC DISORDERS .............................................................................................. 374
CHAPTER 49: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ..................................... 381
CHAPTER 50: ANTIDIABETICS .................................................................................................................... 393
CHAPTER 51: URINARY DISORDERS .......................................................................................................... 404
CHAPTER 52: PREGNANCY AND PRETERM LABOR .................................................................................... 411
CHAPTER 53: LABOR, DELIVERY, AND POSTPARTUM ............................................................................... 422
CHAPTER 54: NEONATAL AND NEWBORN ................................................................................................ 429
CHAPTER 55: WOMEN’S REPRODUCTIVE HEALTH .................................................................................... 432
CHAPTER 56: MEN’S HEALTH AND REPRODUCTIVE DISORDERS .............................................................. 442
CHAPTER 57: SEXUALLY TRANSMITTED INFECTIONS ................................................................................ 448
CHAPTER 58: ADULT AND PEDIATRIC EMERGENCY DRUGS...................................................................... 453
, CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS
APPROACH, 11TH EDITION
MULTIPLE CHOICE
1. ALL OF THE FOLLOWING WOULD BE CONSIDERED SUBJECTIVE DATA, EXCEPT:
A. PATIENT-REPORTED HEALTH HISTORY
B. PATIENT-REPORTED SIGNS AND SYMPTOMS OF THEIR ILLNESS
C. FINANCIAL BARRIERS REPORTED BY THE PATIENT’S CAREGIVER
D. VITAL SIGNS OBTAINED FROM THE MEDICAL RECORD
ANSWER:D
SUBJECTIVE DATA IS BASED ON WHAT PATIENTS OR FAMILY MEMBERS COMMUNICATE TO THE
NURSE. PATIENT- REPORTED HEALTH HISTORY, SIGNS AND SYMPTOMS, AND CAREGIVER REPORTED
FINANCIAL BARRIERS WOULD BE CONSIDERED SUBJECTIVE DATA. VITAL SIGNS OBTAINED FROM THE
MEDICAL RECORD WOULD BE CONSIDERED OBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: PLANNING
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
2. THE NURSE IS USING DATA COLLECTED TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE MOST
DESIRABLE OUTCOMES. WHICH OF THE FOLLOWING STEPS IS THE NURSE APPLYING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. GENERATE SOLUTIONS (PLANNING)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANSWER:C
WHEN GENERATING SOLUTIONS (PLANNING), THE NURSE IDENTIFIES EXPECTED OUTCOMES AND USES
THE PATIENT’S PROBLEM(S) TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE MOST DESIRABLE
OUTCOMES. RECOGNIZING CUES (ASSESSMENT) INVOLVES THE GATHERING OF CUES (INFORMATION)
FROM THE PATIENT ABOUT THEIR HEALTH AND LIFESTYLE PRACTICES, WHICH ARE IMPORTANT FACTS
THAT AID THE NURSE IN MAKING CLINICAL CARE DECISIONS. PRIORITIZING HYPOTHESIS IS USED TO
